Table 3.
Rank probabilities of interventions on efficacy and safety.
| Rank probabilities | 5th | 4th | 3rd | 2nd | 1st |
|---|---|---|---|---|---|
| Efficacy | |||||
| Apixaban | 0.0968187 | 0.1012725 | 0.1571750 | 0.2325012 | 0.4122325 |
| Rivaroxaban | 0.0433725 | 0.0966437 | 0.2026550 | 0.3377875 | 0.3195412 |
| Edoxaban | 0.1649275 | 0.1875575 | 0.2578213 | 0.2289262 | 0.1607675 |
| Dabigatran | 0.2123475 | 0.2640125 | 0.2442575 | 0.1739812 | 0.1054013 |
| Warfarin | 0.4825337 | 0.3505137 | 0.1380912 | 0.0268037 | 0.0020575 |
| Safety | |||||
| Apixaban | 0.0262600 | 0.0395525 | 0.0512362 | 0.1715538 | 0.7113975 |
| Edoxaban | 0.0582387 | 0.0943775 | 0.1248450 | 0.5095350 | 0.2130037 |
| Dabigatran | 0.1773537 | 0.3324900 | 0.2649787 | 0.1668375 | 0.0583400 |
| Warfarin | 0.0368625 | 0.3531388 | 0.4838112 | 0.1169038 | 0.0092837 |
| Rivaroxaban | 0.7012850 | 0.1804412 | 0.0751287 | 0.0351700 | 0.0079750 |
The rank probabilities were used to reflect the hierarchy of drugs, and a larger first-rank probability value symbolized that the drug is more likely to be the best. The results of first-rank probabilities are shown in bold.